Skip to main content

Table 3 Grade 3 or above treatment-related TEAEs occurring in at least 4% of patients in the phase Ib and the phase II trials

From: Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study

Preferred term Phase Ib N (%) Phase II N (%)
  (n=42) Fruquintinib group (n=47) Placebo group (n=24)
Hypertension 9 (21.4) 14 (29.8) 0
HFSR 4 (9.5) 7 (14.9) 0
Diarrhea 4 (9.5) 1 (2.1) 0
Serum sodium decreased 3 (7.1) 0 0
Fatigue 2 (4.8) 2 (4.3) 0
Chest pain 2 (4.8) 0 0
Blood bilirubin increased 1 (2.4) 2 (4.2) 1 (4.2)
AST increased 0 1 (2.1) 1 (4.2)
Platelet count decreased 0 1 (2.1) 1 (4.2)
Blood alkaline phosphatase increased 0 0 2 (8.3)
Myalgia 0 0 1 (4.2)
Coma hepatic 0 0 1 (4.2)
Infection 0 0 1 (4.2)
  1. TEAE treatment-emergent adverse event, HFSR hand-foot skin reaction, AST aspartate aminotransferase